Clinical Trial Update: Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Clinical trial update indicating that JANX014 is being studied in Phase 1 for metastatic castration-resistant prostate cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• JANX014

Snippet

Sponsor: Janux Therapeutics | Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: RECRUITING